ONCOFUCO-for Distributor and Healthcare Professional

Research Driven Adjunct Supplement-ONCOFUCO (former name Oligo Fucoidan)

Hi-Q is dedicated to developing advanced cancer adjunct dietary supplements, powered by our proprietary ingredient OliFuco® Oligo Fucoidan.

Pharmacy Best-Sellers

In Taiwan, our products are trusted by healthcare professionals and available in 3,000+ pharmacies, 500+ clinics, and 23+ hospitals, consistently earning strong recommendations from pharmacists and doctors.

Endorsed by Doctors, Available Everywhere

Taiwan’s leading supplement brand with 3,000+ pharmacies, 500+ clinics, and 23+ hospitals

From Malaysia to Global Markets


We have also expanded into Malaysia’s leading pharmacy chains, including Caring and Big Pharmacy, where our supplements have received excellent reviews. With over 17 years of proven sales performance and professional trust, Hi-Q is now actively expanding across Southeast Asia and building a global presence, delivering reliable health solutions to patients worldwide.

Harness the potential of health supplements to provide valuable assistance in the journey of cancer care

In the realm of healthcare, there exists a distinct division between medications and food. Cancer, undoubtedly, demands the comprehensive approach of medication and professional medical intervention. However, we firmly believe in the significant impact of nutritional support as a valuable adjunct to conventional cancer treatment. At the core of our philosophy lies the understanding that cancer dietary supplements, such as ours, serve as a bridge between pharmaceutical interventions and dietary needs. While medications address the disease at its core, we acknowledge the crucial role of tailored nutritional support in complementing and enhancing the therapeutic outcomes for cancer patients.

Hi-Q’s Greatest Strength
Leading in Human Clinical Trials of OliFuco® Oligo Fucoidan in Cancer Studies and Mechanism Research

Hi-Q collaborates with leading research institutions, hospitals and universities for advanced research and solution. More than 70 international scientific articles were published. Among the articles, over 30 explore oncology, immunomodulation and inflammation studies. Not only animal model-based pre-clinical studies, Hi-Q also invests in more than 10 human clinical trials to prove the efficacy of Oligo Fucoidan. 

Hi-Q’s Significant Milestone in Human Clinical Trial

One significant milestone in our research journey occurred in 2017 when we successfully completed the first double-blind, randomized controlled trial at Kaohsiung Medical University. This landmark trial specifically evaluated the efficacy of OliFuco® as a supplemental therapy in metastatic colorectal cancer patients. The trial conclusively demonstrated the effectiveness of OliFuco® in enhancing the disease control rate among these patients. We are conducting ongoing studies


The scientific studies result show that Oligo fucoidan, whether through in vitro to in vivo research studies or clinical trials in humans, has been proven to produce positive bioactive and synergy effects of adjuvant therapy on cancer treatment. This allows molecular mechanisms in cancer research to be applied in adjunct cancer treatment, in line with the pursuit of translational medicine and the mindset of establishing a direct link between basic medical research and clinical applications


The Next Level of Oligo Fucoidan 
Implication: NCI Drug Dictionary
The NCI Drug Dictionary, issued by National Cancer Institute (NCI) in the United States of America, comprises technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Health professionals as well as the general public can refer to these drug entries to review clinical trials that are listed in NCI's List of Cancer Clinical Trials.OliFuco® (Oligo Fucoidan) has been used in our supplement recommended by doctors and pharmacists to cancer patients, but this is the first time the ingredient is recognized by a credential international institute like NCI. The scientific results of OliFuco® demonstrates the true value of Oligo Fucoidan as a functional ingredient for health and nutraceutical purposes and as an adjuvant supplement.


Global Nutrition Research Project Specialty Award
In 2023, Hi-Q won the esteemed NutraIngredients-Asia Award 2023: The 'Oscar' of Nutritional Ingredients Industry. Hi-Q was awarded the Nutrition Research Project Specialty Award for our project titled " Exploring the Adjunct Therapeutic Potential of OliFuco@ Oligo Fucoidan in Supplemental Intervention for Cancer Cachexia: Enhancing Treatment Outcomes and Improving Quality of Life". This award-winning research project not only represents Hi-Q's outstanding contributions to the global nutrition industry but also provides cancer patients worldwide with more supplemental treatment options.


Making Differences in Cancer Care
  • Enhancing anti-tumor immune response
  • Alleviating side effects of cachexia
  • Improving quality of life
  • Improving treatment tolerance of patients


Seeking Global Distribution Partners

Deliver premium fucoidan solutions backed by science and quality.
B2B distribution opportunities for Finished Products & Raw Materials.

Inquire Now